Risk factors, pathophysiology, and treatment of hot flashes in cancer

CA Cancer Journal for Clinicians

Volumn 63, Issue 3, 2013, Pages 167-192

  Fisher, William I ^a   Johnson, Aimee K ^a   Elkins, Gary R ^a   Otte, Julie L ^b   Burns, Debra S ^c   Yu, Menggang ^d   Carpenter, Janet S ^b  

^a BAYLOR UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

hot flashes; menopause; neoplasms; palliative care; sweating

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLONIDINE; CYTOCHROME P450; DESVENLAFAXINE; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; GLUCOSE; HERBACEOUS AGENT; METHYLDOPA; MIRTAZAPINE; MOCLOBEMIDE; NORADRENALIN; PAROXETINE; PHYTOESTROGEN; SEROTONIN; SERTRALINE; TIBOLONE; UNINDEXED DRUG; VENLAFAXINE; VERALIPRIDE; VITAMIN;

AGE; AGGRESSION; AGITATION; ALTERNATIVE MEDICINE; ANEMIA; ANXIETY; ANXIETY DISORDER; ASTHENIA; ATAXIA; ATTRIBUTABLE RISK; BEHAVIOR CHANGE; BEHAVIOR THERAPY; BLEEDING DISORDER; BLURRED VISION; BODY MASS; BRADYCARDIA; BREAST CANCER; BRONCHOSPASM; CANCER RADIOTHERAPY; CARDIOVASCULAR RISK; CHOREOATHETOSIS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSURIA; EDEMA; EDUCATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; ETHNICITY; FATIGUE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HALLUCINATION; HEARING IMPAIRMENT; HEART BEAT; HEPATITIS; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOGLYCEMIA; HYPOMANIA; INCREASED APPETITE; INFECTION; INSOMNIA; IRRITABILITY; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MANIA; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; NAUSEA; NERVOUSNESS; NEUROCHEMISTRY; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; ORCHIECTOMY; PATHOPHYSIOLOGY; PATIENT DECISION MAKING; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOTHERAPY; RACE; REVIEW; RISK ASSESSMENT; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SMOKING; SOMNOLENCE; SPEECH DISORDER; STOMACH ULCER; SUICIDE; TACHYCARDIA; THERMOREGULATION; THORAX PAIN; TOXIC EPIDERMAL NECROLYSIS; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; AUTONOMIC NERVE BLOCK; BODY TEMPERATURE REGULATION; CHOLINERGIC ANTAGONISTS; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; HOT FLASHES; HUMANS; NEOPLASMS; PHYTOTHERAPY; RISK FACTORS; STELLATE GANGLION; VITAMINS;

EID: 84877306394     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21171     Document Type: Review

References (271)

1. Woodward S, Greville H, Freedman RR,. Ventilatory response during menopausal hot flashes. Menopause. 1995; 2: 81-88.
2. Kronenberg F,. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990; 592: 52-86; discussion 123-133.
3. Kronenberg F, Cote LJ, Linkie DM, Dyrenfurth I, Downey JA,. Menopausal hot flashes: thermoregulatory, cardiovascular, and circulating catecholamine and LH changes. Maturitas. 1984; 6: 31-43.
4. Freedman RR,. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril. 1998; 70: 332-337.
5. Carpenter JS, Andrykowski MA, Freedman RR, Munn R,. Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause. 1999; 6: 209-215.
6. Carpenter JS, Gilchrist JM, Chen K, Gautam S, Freedman RR,. Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause. 2004; 11: 375-381.
7. Carpenter JS,. State of the science: hot flashes and cancer. Part 1: definition, scope, impact, physiology, and measurement. Oncol Nurs Forum. 2005; 32: 959-968.
8. Kronenberg F,. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol. 1994; 29: 319-336.
9. Freeman EW, Sherif K,. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007; 10: 197-214.
10. Carpenter JS, Johnson D, Wagner L, Andrykowski M,. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum. 2002; 29: E16-E25.
11. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA,. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002; 23: 501-509.
12. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004; 15: 753-760.
13. Schow DA, Renfer LG, Rozanski TA, Thompson IM,. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998; 91: 855-857.
14. Spetz AC, Hammar M, Lindberg B, Spangberg A, Varenhorst E,; Scandinavian Prostatic Cancer Group-5 Trial Study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001; 166: 517-520.
15. Schnirer II, Yao JC, Ajani JA,. Carcinoid-a comprehensive review. Acta Oncol. 2003; 42: 672-692.
16. Mohyi D, Tabassi K, Simon J,. Differential diagnosis of hot flashes. Maturitas. 1997; 27: 203-214.
17. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G,. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage. 2000; 19: 436-445.
18. Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K,. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol. 2004; 11: 735-741.
19. Spetz AC, Zetterlund EL, Varenhorst E, Hammar M,. Incidence and management of hot flashes in prostate cancer. J Support Oncol. 2003; 1: 263-266, 269-270, 272-273; discussion 267-268, 271-272.
20. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM,. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004; 22: 4951-4957.
21. Avis NE, Brockwell S, Colvin A,. A universal menopausal syndrome? Am J Med. 2005; 118 (suppl 12B): 37-46.
22. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG,. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000; 96: 351-358.
23. Spetz AC, Fredriksson MG, Hammar ML,. Hot flushes in a male population aged 55, 65, and 75 years, living in the community of Linkoping, Sweden. Menopause. 2003; 10: 81-87.
24. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001; 52: 345-356.
25. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000; 152: 463-473.
26. Grisso JA, Freeman EW, Maurin E, Garcia-Espana B, Berlin JA,. Racial differences in menopause information and the experience of hot flashes. J Gen Intern Med. 1999; 14: 98-103.
27. Savard MH, Savard J, Quesnel C, Ivers H,. The influence of breast cancer treatment on the occurrence of hot flashes. J Pain Symptom Manage. 2009; 37: 687-697.
28. Blumel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause. 2011; 18: 778-785.
29. Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. BJOG. 2012; 119: 40-50.
30. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA,. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003; 101: 264-272.
31. Kuh DL, Wadsworth M, Hardy R,. Women's health in midlife: the influence of the menopause, social factors and health in earlier life. Br J Obstet Gynaecol. 1997; 104: 923-933.
32. Avis NE, Crawford SL, McKinlay SM,. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health. 1997; 3: 103-120.
33. Hayatbakhsh MR, Clavarino A, Williams GM, Sina M, Najman JM,. Cigarette smoking and age of menopause: a large prospective study. Maturitas. 2012; 72: 346-352.
34. Longcope C, Johnston CC Jr,. Androgen and estrogen dynamics in pre- and postmenopausal women: a comparison between smokers and nonsmokers. J Clin Endocrinol Metab. 1988; 67: 379-383.
35. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J,. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 1986; 315: 1305-1309.
36. Barbieri RL, McShane PM, Ryan KJ,. Constituents of cigarette smoke inhibit human granulosa cell aromatase. Fertil Steril. 1986; 46: 232-236.
37. Mattison DR,. The mechanisms of action of reproductive toxins. Am J Ind Med. 1983; 4: 65-79.
38. Thurston RC, Christie IC, Matthews KA,. Hot flashes and cardiac vagal control: a link to cardiovascular risk? Menopause. 2010; 17: 456-461.
39. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA,. Hot flashes and carotid intima media thickness among midlife women. Menopause. 2011; 18: 352-358.
40. Schwingl PJ, Hulka BS, Harlow SD,. Risk factors for menopausal hot flashes. Obstet Gynecol. 1994; 84: 29-34.
41. Whiteman MK, Staropoli CA, Benedict JC, Borgeest C, Flaws JA,. Risk factors for hot flashes in midlife women. J Womens Health (Larchmt). 2003; 12: 459-472.
42. Crandall CJ, Crawford SL, Gold EB,. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med. 2006; 119 (9 suppl 1): S52-S60.
43. Schneider BP, Radovich M, Flockhart DA, et al. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. Breast Cancer Res Treat. 2009; 116: 543-549.
44. Woods NF, Mitchell ES, Viernes H, Janssen P, Farrin F,. CYP17, CYP19, and ESR polymorphisms and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Paper presented at: North American Menopause Society 15th Annual Meeting; October 6-9, 2004; Washington, DC.
45. Massad-Costa AM, Nogueira-de-Souza NC, de Carvalho CV, et al. CYP17 polymorphism and hot flushes in postmenopausal women. Climacteric. 2008; 11: 404-408.
46. Nogueira RC Jr, Costa AM, Silva ID, et al. Influence of the CYP17 polymorphism on vasomotor symptoms in postmenopausal women: a pilot study. Climacteric. 2011; 14: 537-543.
47. Visvanathan K, Gallicchio L, Schilling C, et al. Cytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women. Obstet Gynecol. 2005; 106: 1372-1381.
48. Dennerstein L, Lehert P, Burger HG, Guthrie JR,. New findings from non-linear longitudinal modelling of menopausal hormone changes. Hum Reprod Update. 2007; 13: 551-557.
49. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001; 19: 2596-2606.
50. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer. 1998; 82: 1682-1691.
51. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003; 45: 29-38.
52. Lo Presti A, Ruvolo G, Gancitano RA, Cittadini E,. Ovarian function following radiation and chemotherapy for cancer. Eur J Obstet Gynecol Reprod Biol. 2004; 113 (suppl 1): S33-S40.
53. Kouriefs C, Georgiou M, Ravi R,. Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. 2002; 89: 379-383.
54. Holzbeierlein JM, Castle E, Thrasher JB,. Complications of androgen deprivation therapy: prevention and treatment. Oncology (Williston Park). 2004; 18: 303-309.
55. Freedman RR,. Menopausal hot flashes. In:, Lobo RA, Kelsey J, Marcus R, eds. Menopause: Biology and Pathobiology. San Diego, CA: Academic Press; 2000: 215-227.
56. Freedman RR,. Physiology of hot flashes. Am J Hum Biol. 2001; 13: 453-464.
57. Acs N, Vajo Z, Demendi C, Nadasy G, Monos E, Szekacs B,. Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes? Gynecol Endocrinol. 2001; 15: 68-73.
58. Rossmanith WG, Ruebberdt W,. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol. 2009; 25: 303-314.
59. Carpenter JS, Gautam S, Freedman RR, Andrykowski M,. Circadian rhythm of objectively recorded hot flashes in postmenopausal breast cancer survivors. Menopause. 2001; 8: 181-188.
60. Freedman RR, Krell W,. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol. 1999; 181: 66-70.
61. Freedman RR, Norton D, Woodward S, Cornelissen G,. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab. 1995; 80: 2354-2358.
62. Freedman RR, Woodward S,. Core body temperature during menopausal hot flushes. Fertil Steril. 1996; 65: 1141-1144.
63. Freedman RR,. Hot flashes revisited. Menopause. 2000; 7: 3-4.
64. North American Menopause Society. Menopause Practice: A Clinician's Guide. 4th ed. Mayfield Heights, OH: North American Menopause Society; 2010.
65. Bellino FL, Wise PM,. Nonhuman primate models of menopause workshop. Biol Reprod. 2003; 68: 10-18.
66. MacLeay JM, Lehmer E, Enns RM, Mallinckrodt C, Bryant HU, Turner AS,. Central and peripheral temperature changes in sheep following ovariectomy. Maturitas. 2003; 46: 231-238.
67. Freedman RR, Blacker CM,. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril. 2002; 77: 487-490.
68. Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric. 2011; 14: 515-528.
69. Berendsen HH,. The role of serotonin in hot flushes. Maturitas. 2000; 36: 155-164.
70. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D,. Hot flushes. Lancet. 2002; 360: 1851-1861.
71. Gonzales GF, Carrillo C,. Blood serotonin levels in postmenopausal women: effects of age and serum oestradiol levels. Maturitas. 1993; 17: 23-29.
72. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K,. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry. 1995; 37: 434-441.
73. Sipe K, Leventhal L, Burroughs K, Cosmi S, Johnston GH, Deecher DC,. Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res. 2004; 1028: 191-202.
74. Bethea CL, Mirkes SJ, Shively CA, Adams MR,. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry. 2000; 47: 562-576.
75. Lu NZ, Bethea CL,. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology. 2002; 27: 12-24.
76. Chen Y, Lu X, Huang Y, Xin X, Ye X,. Changes of plasma serotonin precursor metabolite concentrations in postmenopausal women with hot flushes [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2002; 37: 726-728.
77. Carpenter JS, Yu M, Wu J, et al. Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. Menopause. 2009; 16: 644-652.
78. Hay DL, Poyner DR,. Calcitonin gene-related peptide, adrenomedullin and flushing. Maturitas. 2009; 64: 104-108.
79. Chen JT, Hirai Y, Seimiya Y, Hasumi K, Shiraki M,. Menopausal flushes and calcitonin-gene-related peptide. Lancet. 1993; 342: 49.
80. Valentini A, Petraglia F, De Vita D, et al. Changes of plasma calcitonin gene-related peptide levels in postmenopausal women. Am J Obstet Gynecol. 1996; 175 (3 pt 1): 638-642.
81. Gupta P, Harte A, Sturdee DW, et al. Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. Climacteric. 2008; 11: 364-372.
82. Chen JT, Shiraki M,. Menopausal hot flash and calciotonin gene-related peptide; effect of Keishi-bukuryo-gan, a kampo medicine, related to plasma calciotonin gene-related peptide level. Maturitas. 2003; 45: 199-204.
83. Wyon YA, Spetz AC, Theodorsson GE, Hammar ML,. Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women. Menopause. 2000; 7: 25-30.
84. Wyon Y, Frisk J, Lundeberg T, Theodorsson E, Hammar M,. Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Maturitas. 1998; 30: 289-294.
85. Yuzurihara M, Ikarashi Y, Noguchi M, Kase Y, Takeda S, Aburada M,. Involvement of calcitonin gene-related peptide in elevation of skin temperature in castrated male rats. Urology. 2003; 62: 947-951.
86. Yuzurihara M, Ikarashi Y, Noguchi M, Kase Y, Takeda S, Aburada M,. Prevention by 17beta-estradiol and progesterone of calcitonin gene-related peptide-induced elevation of skin temperature in castrated male rats. Urology. 2004; 64: 1042-1047.
87. Spetz AC, Pettersson B, Varenhorst E, Theodorsson E, Thorell LH, Hammar M,. Momentary increase in plasma calcitonin gene-related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. J Urol. 2001; 166: 1720-1723.
88. Holm AC, Thorell LH, Theodorsson E, Hammar M,. Hot flushes in healthy aging men differ from those in men with prostate cancer and in menopausal women. Gynecol Endocrinol. 2012; 28: 72-75.
89. Dormire SL, Reame NK,. Menopausal hot flash frequency changes in response to experimental manipulation of blood glucose. Nurs Res. 2003; 52: 338-343.
90. Dormire SL, Howharn C,. The effect of dietary intake on hot flashes in menopausal women. J Obstet Gynecol Neonatal Nurs. 2007; 36: 255-262.
91. Tuomikoski P, Ylikorkala O, Mikkola TS,. Menopausal hot flashes and insulin resistance. Menopause. 2012; 19: 1116-1120.
92. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA,. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause. 2009; 16: 883-887.
93. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000; 356: 2059-2063.
94. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998; 16: 2377-2381.
95. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 2007; 12: 124-135.
96. Buijs C, Mom CH, Willemse PH, et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat. 2009; 115: 573-580.
97. Irani J, Salomon L, Oba R, Bouchard P, Mottet N,. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010; 11: 147-154.
98. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010; 28: 3278-3283.
99. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000; 11: 17-22.
100. Weitzner MA, Moncello J, Jacobsen PB, Minton S,. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage. 2002; 23: 337-345.
101. Stearns V, Beebe KL, Iyengar M, Dube E,. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003; 289: 2827-2834.
102. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005; 23: 6919-6930.
103. Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc. 2004; 79: 1247-1251.
104. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002; 20: 1578-1583.
105. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB,. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006; 12: 114-122.
106. Wu MF, Hilsenbeck SG, Tham YL, et al. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2009; 118: 369-375.
107. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004; 2: 50-56.
108. Biglia N, Kubatzki F, Sgandurra P, et al. Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J. 2007; 13: 490-495.
109. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366: 818-824.
110. Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009; 20: 542-549.
111. Moraska AR, Atherton PJ, Szydlo DW, et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study-NCCTG Trial N00CB. J Support Oncol. 2010; 8: 128-132.
112. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994; 12: 155-158.
113. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000; 132: 788-793.
114. Bressler LR, Murphy CM, Shevrin DH, Warren RF,. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Ann Pharmacother. 1993; 27: 182-185.
115. Parra RO, Gregory JG,. Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine. J Urol. 1990; 143: 753-754.
116. Loprinzi CL, Goldberg RM, O'Fallon JR, et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol. 1994; 151: 634-636.
117. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994; 331: 347-352.
118. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998; 82: 1784-1788.
119. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008; 26: 1650-1656.
120. Sismondi P, Kimmig R, Kubista E, et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients-data from LIBERATE trial. Maturitas. 2011; 70: 365-372.
121. Dimitrakakis C, Keramopoulos D, Vourli G, Gaki V, Bredakis N, Keramopoulos A,. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric. 2005; 8: 342-351.
122. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG. 2005; 112: 228-233.
123. Pollow K, Schaffrath M, Kolbl H, et al. Phase II study of goserelin adjunctive therapy combined with exemestane with or without tibolone in premenopausal with receptor positive, node negative mammary carcinoma: ADAGIO Study. Geburtsh Frauenheilk. 2005; 65: 612-619.
124. Joffe H, Partridge A, Giobbie-Hurder A, et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010; 17: 908-916.
125. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001; 19: 2739-2745.
126. Al-Akoum M, Maunsell E, Verreault R, Provencher L, Otis H, Dodin S,. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause. 2009; 16: 307-314.
127. Thompson EA, Reilly D,. The homeopathic approach to the treatment of symptoms of oestrogen withdrawal in breast cancer patients. A prospective observational study. Homeopathy. 2003; 92: 131-134.
128. Jacobs J, Herman P, Heron K, Olsen S, Vaughters L,. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. J Altern Complement Med. 2005; 11: 21-27.
129. Thompson EA, Montgomery A, Douglas D, Reilly D,. A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors. J Altern Complement Med. 2005; 11: 13-20.
130. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998; 16: 495-500.
131. Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric. 2009; 12: 310-318.
132. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000; 18: 1068-1074.
133. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002; 20: 1449-1455.
134. Sharma P, Wisniewski A, Braga-Basaria M, et al. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009; 182: 2265-2272.
135. Pruthi S, Qin R, Terstreip SA, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 2012; 19: 48-53.
136. Hervik J, Mjaland O,. Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial. Breast Cancer Res Treat. 2009; 116: 311-316.
137. Deng G, Vickers A, Yeung S, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol. 2007; 25: 5584-5590.
138. Frisk J, Kallstrom AC, Wall N, Fredrikson M, Hammar M,. Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes. Support Care Cancer. 2012; 20: 715-724.
139. Nedstrand E, Wijma K, Wyon Y, Hammar M,. Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study. Climacteric. 2005; 8: 243-250.
140. Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010; 28: 634-640.
141. Davies FM,. The effect of acupuncture treatment on the incidence and severity of hot flushes experienced by women following treatment for breast cancer: a comparison of traditional and minimal acupuncture. Eur J Cancer. 2001; 37: S438.
142. Ashamalla H, Jiang ML, Guirguis A, Peluso F, Ashamalla M,. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. Int J Radiat Oncol Biol Phys. 2011; 79: 1358-1363.
143. Beer TM, Benavides M, Emmons SL, et al. Acupuncture for hot flashes in patients with prostate cancer. Urology. 2010; 76: 1182-1188.
144. Carson JW, Carson KM, Porter LS, Keefe FJ, Seewaldt VL,. Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer. 2009; 17: 1301-1309.
145. Fenlon DR, Corner JL, Haviland JS,. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage. 2008; 35: 397-405.
146. Carpenter JS, Burns DS, Wu J, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial [published online ahead of print August 31, 2012]. J Gen Intern Med.
147. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008; 26: 5022-5026.
148. Elkins G, Marcus J, Stearns V, Hasan Rajab M,. Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology. 2007; 16: 487-492.
149. Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N,. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause. 2011; 18: 611-620.
150. Ayers B, Smith M, Hellier J, Mann E, Hunter MS,. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012; 19: 749-759.
151. Mitchell SA, Friese CR,. ONS PEP (Putting Evidence into Practice) Weight of Evidence Classification Schema: Decision Rules for Summative Evaluation of a Body of Evidence. ons.org/Research/media/ons/docs/research/outcomes/weight-of- evidence-table.pdf. Accessed October 17, 2012.
152. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97: 30-39.
153. Schober CE, Ansani NT,. Venlafaxine hydrochloride for the treatment of hot flashes. Ann Pharmacother. 2003; 37: 1703-1707.
154. Barton D, La Vasseur B, Loprinzi C, Novotny P, Wilwerding MB, Sloan J,. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum. 2002; 29: 33-40.
155. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB,. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005; 105: 161-166.
156. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012; 15: 12-20.
157. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S,. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009; 200: 238.e1-238.e10.
158. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause. 2006; 13: 780-786.
159. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011; 305: 267-274.
160. Carpenter JS, Guthrie KA, Larson JC, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril. 2012; 97: 1399-1404.
161. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005; 12: 18-26.
162. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006; 295: 2057-2071.
163. Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C,. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause. 2009; 16: 477-483.
164. Gordon PR, Kerwin JP, Boesen KG, Senf J,. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause. 2006; 13: 568-575.
165. Waldinger MD, Berendsen HH, Schweitzer DH,. Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000; 36: 165-168.
166. Tarim E, Bagis T, Kilicdag E, Erkanli S, Aslan E, Kuscu E,. Moclobemide in the treatment of hot flashes in postmenopausal women. Adv Ther. 2002; 19: 258-265.
167. Hall E, Frey BN, Soares CN,. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs. 2011; 71: 287-304.
168. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC,. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci. 2007; 28: 220-228.
169. Aguirre W, Chedraui P, Mendoza J, Ruilova I,. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol. 2010; 26: 333-337.
170. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R,. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008; 15: 310-318.
171. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K,. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003; 101: 337-345.
172. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006; 108: 41-48.
173. Guttuso TJ Jr,. Gabapentin's effects on hot flashes and hypothermia. Neurology. 2000; 54: 2161-2163.
174. Jeffery SM, Pepe JJ, Popovich LM, Vitagliano G,. Gabapentin for hot flashes in prostate cancer. Ann Pharmacother. 2002; 36: 433-436.
175. Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007; 25: 308-312.
176. Clayden JR, Bell JW, Pollard P,. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J. 1974; 1: 409-412.
177. Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM,. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas. 1987; 9: 227-234.
178. Lebherz TB, French L,. Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer. Obstet Gynecol. 1969; 33: 795-799.
179. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol. 2002; 13: 883-888.
180. Sartor O, Eastham JA,. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J. 1999; 92: 415-416.
181. Kloosterboer HJ,. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001; 76: 231-238.
182. Palacios S,. Tibolone: what does tissue specific activity mean? Maturitas. 2001; 37: 159-165.
183. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ,. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003; 68: 21-30.
184. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005; 142 (12 pt 1): 1003-1013.
185. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K,. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998; 105: 904-911.
186. Beral V,; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362: 419-427.
187. Cummings SR, Ettinger B, Delmas PD, et al. LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008; 359: 697-708.
188. Kenemans P, Bundred NJ, Foidart JM, et al. LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised non-inferiority trial. Lancet Oncol. 2009; 10: 135-146.
189. Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta K, Kaufmann M,. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients-a double-blind, randomized study. Ann Oncol. 2007; 18: 689-693.
190. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009; 27: 2831-2837.
191. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011; 29: 3862-3868.
192. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006; 24: 1409-1414.
193. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010; 28: 5147-5152.
194. Geller SE, Studee L,. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt). 2005; 14: 634-649.
195. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003; 51: 5661-5670.
196. Farnsworth NR, Mahady GB,. Research highlights from the UIC/NIH Center for Botanical Dietary Supplements Research for Women's Health: black cohosh from the field to the clinic. Pharm Biol. 2009; 47: 755-760.
197. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A,. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med. 2010; 16: 36-44.
198. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause. 2009; 16: 1156-1166.
199. van der Sluijs CP, Bensoussan A, Chang S, Baber R,. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause. 2009; 16: 336-344.
200. Hernandez Munoz G, Pluchino S,. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003; 44 (suppl 1): S59-S65.
201. Rostock M, Fischer J, Mumm A, Stammwitz U, Saller R, Bartsch HH,. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints-a prospective observational study. Gynecol Endocrinol. 2011; 27: 844-848.
202. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006; 24: 2836-2841.
203. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R,. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause. 2011; 18: 366-375.
204. Teschke R,. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause. 2010; 17: 426-440.
205. Abdali K, Khajehei M, Tabatabaee HR,. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause. 2010; 17: 326-331.
206. van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ,. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause. 2009; 16: 156-163.
207. Caraci F, Crupi R, Drago F, Spina E,. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab. 2011; 12: 570-577.
208. Rahimi R, Abdollahi M,. An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012; 8: 691-708.
209. Clover A, Ratsey D,. Homeopathic treatment of hot flushes: a pilot study. Homeopathy. 2002; 91: 75-79.
210. Bordet MF, Colas A, Marijnen P, Masson J, Trichard M,. Treating hot flushes in menopausal women with homeopathic treatment-results of an observational study. Homeopathy. 2008; 97: 10-15.
211. Christy CJ,. Vitamin E in menopause. Am J Obstet Gynecol. 1945; 50: 84-87.
212. Ziaei S, Kazemnejad A, Zareai M,. The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest. 2007; 64: 204-207.
213. Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ,. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011; 4: 158-170.
214. Andrikoula M, Baker D, Nesic J, Liao LM, Duka T, Prelevic GM,. The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women. Climacteric. 2011; 14: 544-550.
215. Gaweesh SS, Abdel-Gawad MM, Nagaty AM, Ewies AA,. Folic acid supplementation may cure hot flushes in postmenopausal women: a prospective cohort study. Gynecol Endocrinol. 2010; 26: 658-662.
216. Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M,. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012; 19: 776-790.
217. Bolanos R, Del Castillo A, Francia J,. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause. 2010; 17: 660-666.
218. Messina M, Kucuk O, Lampe JW,. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int. 2006; 89: 1121-1134.
219. Piersen CE, Booth NL, Sun Y, et al. Chemical and biological characterization and clinical evaluation of botanical dietary supplements: a phase I red clover extract as a model. Curr Med Chem. 2004; 11: 1361-1374.
220. van de Weijer PH, Barentsen R,. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas. 2002; 42: 187-193.
221. Lewis JE, Nickell LA, Thompson LU, Szalai JP, Kiss A, Hilditch JR,. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause. 2006; 13: 631-642.
222. Simbalista RL, Sauerbronn AV, Aldrighi JM, Areas JA,. Consumption of a flaxseed-rich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr. 2010; 140: 293-297.
223. Lipov E, Lipov S, Stark JT,. Stellate ganglion blockade provides relief from menopausal hot flashes: a case report series. J Womens Health (Larchmt). 2005; 14: 737-741.
224. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol. 2008; 9: 523-532.
225. Pachman DR, Barton D, Carns PE, et al. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer. 2011; 19: 941-947.
226. Haest K, Kumar A, Van Calster B, et al. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Ann Oncol. 2012; 23: 1449-1454.
227. Lee MS, Shin BC, Ernst E,. Acupuncture for treating menopausal hot flushes: a systematic review. Climacteric. 2009; 12: 16-25.
228. Lee MS, Kim KH, Choi SM, Ernst E,. Acupuncture for treating hot flashes in breast cancer patients: a systematic review. Breast Cancer Res Treat. 2009; 115: 497-503.
229. Lee MS, Kim KH, Shin BC, Choi SM, Ernst E,. Acupuncture for treating hot flushes in men with prostate cancer: a systematic review. Support Care Cancer. 2009; 17: 763-770.
230. Borud EK, Alraek T, White A, et al. The Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study, a randomized controlled trial. Menopause. 2009; 16: 484-493.
231. Borud EK, Alraek T, White A, Grimsgaard S,. The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. Menopause. 2010; 17: 262-268.
232. de Valois BA, Young TE, Robinson N, McCourt C, Maher EJ,. Using traditional acupuncture for breast cancer-related hot flashes and night sweats. J Altern Complement Med. 2010; 16: 1047-1057.
233. Otte JL, Carpenter JS, Zhong X, Johnstone PA,. Feasibility study of acupuncture for reducing sleep disturbances and hot flashes in postmenopausal breast cancer survivors. Clin Nurs Spec. 2011; 25: 228-236.
234. Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010; 28: 634-640.
235. Williamson J, White A, Hart A, Ernst E,. Randomised controlled trial of reflexology for menopausal symptoms. BJOG. 2002; 109: 1050-1055.
236. Daley A, Stokes-Lampard H, Macarthur C,. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2011 (5): CD006108.
237. Ogwumike OO, Sanya AO, Arowojolu AO,. Endurance exercise effect on quality of life and menopausal symptoms in Nigerian women. Afr J Med Med Sci. 2011; 40: 187-195.
238. Riesco E, Choquette S, Audet M, Tessier D, Dionne IJ,. Effect of exercise combined with phytoestrogens on quality of life in postmenopausal women. Climacteric. 2011; 14: 573-580.
239. Aiello EJ, Yasui Y, Tworoger SS, et al. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause. 2004; 11: 382-388.
240. Elavsky S, Gonzales JU, Proctor DN, Williams N, Henderson VW,. Effects of physical activity on vasomotor symptoms: examination using objective and subjective measures. Menopause. 2012; 19: 1095-1103.
241. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH,. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010; 4: 87-100.
242. Smith KB, Pukall CF,. An evidence-based review of yoga as a complementary intervention for patients with cancer. Psychooncology. 2009; 18: 465-475.
243. Lee MS, Kim JI, Ha JY, Boddy K, Ernst E,. Yoga for menopausal symptoms: a systematic review. Menopause. 2009; 16: 602-608.
244. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H,. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001; 19: 4280-4290.
245. Cohen L, Warneke C, Fouladi RT, Rodriguez MA, Chaoul-Reich A,. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer. 2004; 100: 2253-2260.
246. Galantino ML, Greene L, Archetto B, et al. A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias. Explore (NY). 2012; 8: 40-47.
247. Kovacic T, Kovacic M,. Impact of relaxation training according to Yoga In Daily Life® system on self-esteem after breast cancer surgery. J Altern Complement Med. 2011; 17: 1157-1164.
248. Lengacher CA, Reich RR, Post-White J, et al. Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters. J Behav Med. 2012; 35: 86-94.
249. Banasik J, Williams H, Haberman M, Blank SE, Bendel R,. Effect of Iyengar yoga practice on fatigue and diurnal salivary cortisol concentration in breast cancer survivors. J Am Acad Nurse Pract. 2011; 23: 135-142.
250. Danhauer SC, Mihalko SL, Russell GB, et al. Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychooncology. 2009; 18: 360-368.
251. Thomas R, Shaw RM,. Yoga for women living with breast cancer-related arm morbidity: findings from an exploratory study. Int J Yoga Therap. 2011;(21): 39-48.
252. Raghavendra RM, Nagarathna R, Nagendra HR, et al. Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. Eur J Cancer Care (Engl). 2007; 16: 462-474.
253. Kovacic T, Kovacic M,. Impact of relaxation training according to Yoga In Daily Life® system on perceived stress after breast cancer surgery. Integr Cancer Ther. 2011; 10: 16-26.
254. Littman AJ, Bertram LC, Ceballos R, et al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures. Support Care Cancer. 2012; 20: 267-277.
255. Ulger O, Yagli NV,. Effects of yoga on the quality of life in cancer patients. Complement Ther Clin Pract. 2010; 16: 60-63.
256. Van Puymbroeck M, Schmid A, Shinew KJ, Hsieh PC,. Influence of Hatha yoga on physical activity constraints, physical fitness, and body image of breast cancer survivors: a pilot study. Int J Yoga Therap. 2011;(21): 49-60.
257. Vadiraja HS, Rao MR, Nagarathna R, et al. Effects of yoga program on quality of life and affect in early breast cancer patients undergoing adjuvant radiotherapy: a randomized controlled trial. Complement Ther Med. 2009; 17: 274-280.
258. Rao MR, Raghuram N, Nagendra HR, et al. Anxiolytic effects of a yoga program in early breast cancer patients undergoing conventional treatment: a randomized controlled trial. Complement Ther Med. 2009; 17: 1-8.
259. Tremblay A, Sheeran L, Aranda SK,. Psychoeducational interventions to alleviate hot flashes: a systematic review. Menopause. 2008; 15: 193-202.
260. Germaine LM, Freedman RR,. Behavioral treatment of menopausal hot flashes: evaluation by objective methods. J Consult Clin Psychol. 1984; 52: 1072-1079.
261. Stevenson DW, Delprato DJ,. Multiple component self-control program for menopausal hot flashes. J Behav Ther Exp Psychiatry. 1983; 14: 137-140.
262. Freedman RR, Woodward S,. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol. 1992; 167: 436-439.
263. Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R,. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol. 1996; 17: 202-207.
264. Wijma K, Melin A, Nedstrand E, Hammar M,. Treatment of menopausal symptoms with applied relaxation: a pilot study. J Behav Ther Exp Psychiatry. 1997; 28: 251-261.
265. Freedman RR, Woodward S, Brown B, Javiad JI, Pandey GN,. Biochemical and thermoregulatory effects of behavioral treatment for menopausal hot flashes. Menopause. 1995; 2: 211-218.
266. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ,. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial [published online ahead of print October 22, 2012]. Menopause.
267. Carmody J, Crawford S, Churchill L,. A pilot study of mindfulness-based stress reduction for hot flashes. Menopause. 2006; 13: 760-769.
268. Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL,. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun. 2008; 22: 969-981.
269. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR,. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst. 2000; 92: 1054-1064.
270. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012; 13: 309-318.
271. Mann E, Smith M, Hellier J, Hunter MS,. A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol. BMC Cancer. 2011; 11: 44.